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Abstract
Background: Patient and public involvement in research (PPIR) may improve trial recruitment rates, but it is unclear
how. Where trials use PPIR to improve design and conduct, many do not communicate this clearly to potential
participants. Better communication of PPIR might encourage patient enrolment, as trials may be perceived as more
socially valid, relevant and trustworthy. We aimed to evaluate the impact on recruitment of directly advertising PPIR
to potential trial participants.
Methods: This is a cluster trial, embedded within a host trial (‘EQUIP’) recruiting service users diagnosed with severe
mental illness. The intervention was informed by a systematic review, a qualitative study, social comparison theory
and a stakeholder workshop including service users and carers. Adopting Participatory Design approaches, we
co-designed the recruitment intervention with PPIR partners using a leaflet to advertise the PPIR in EQUIP and
sent potential participants invitations with the leaflet (intervention group) or not (control group). Primary outcome was
the proportion of patients enrolled in EQUIP. Secondary outcomes included the proportions of patients who positively
responded to the trial invitation.
Results: Thirty-four community mental health teams were randomised and 8182 service users invited. For the primary
outcome, 4% of patients in the PPIR group were enrolled versus 5.3% of the control group. The intervention was not
effective for improving recruitment rates (adjusted OR = 0.75, 95% CI = 0.53 to 1.07, p = 0.113). For the secondary
outcome of positive response, the intervention was not effective, with 7.3% of potential participants in the intervention
group responding positively versus 7.9% of the control group (adjusted OR = 0.74, 95% CI = 0.53 to 1.04, p = 0.082). We
did not find a positive impact of directly advertising PPIR on any other outcomes.
Conclusion: To our knowledge, this is the largest ever embedded trial to evaluate a recruitment or PPIR intervention.
Advertising PPIR did not improve enrolment rates or any other outcome. It is possible that rather than advertising PPIR
being the means to improve recruitment, PPIR may have an alternative impact on trials by making them more
attractive, acceptable and patient-centred. We discuss potential reasons for our findings and implications for
recruitment practice and research.
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Background
Randomised controlled trials are the ‘gold standard’ for
evaluating treatments, yet recruitment into trials re-
mains a great challenge, with approximately 45% of pub-
licly funded and 80% of industry-funded trials failing to
meet their recruitment targets [1, 2]. Mental health dis-
orders are the leading cause of disability among adults
worldwide [3]; however, trials enrolling patients with
mental health problems experience even greater recruit-
ment challenges [4–7]. These challenges stem from vari-
ous sources including stigma [8] and issues related to
the diagnosis adversely impacting on the patient’s ability
and motivation to participate in research [9]. Inability to
recruit into a trial adversely impacts trials by reducing
the total sample size (which limits internal validity) and
the proportion of eligible participants who are recruited
(which limits external validity).
Thus there is a need to develop and test interventions
to improve recruitment. One method is to ‘embed’ trials
of recruitment interventions in ongoing trials; however,
such trials are rare. Systematic reviews of trial recruit-
ment interventions have highlighted the need for more
embedded recruitment trials [10, 11]. Recent initiatives
have also increasingly called for the development and
evaluation of interventions for recruiting and retaining
participants in trials [11–16].
We have developed methodological, logistical and
reporting frameworks for embedded recruitment trials
[12, 17] and assessed their feasibility using interventions
such as an improved Participant Information Sheet and
a multimedia decision aid [18, 19]. The eventual aim is
to make delivery of embedded recruitment trials a rou-
tine activity, to assist the rapid development of recruit-
ment to meet health and policy goals [20].
Patient and public involvement in research (PPIR), also
known, among other terms, as ‘user involvement’, is re-
search being carried out ‘with’ or ‘by’ patients and/or
members of the public rather than ‘to’, ‘about’ or ‘for’
them [21]. This definition of PPIR is broad and involves
patients, all groups who represent patients, as well as
members of the public taking roles in the development,
conduct and governance of research [22–24]. PPIR is
thought to be crucial because it produces ‘better’
patient-focussed research by offering unique, invaluable
insights into its prioritization, design, implementation
and evaluation, making trials more effective and credible
[25, 26]. PPIR is well-established as public policy in the
United Kingdom (UK) and other developed countries
and is increasingly mandated for publicly funded trials
[27–30]. However, quantitative evidence around its im-
pact is sparse, and that which exists is of poor quality
and lacking in rigour [31]. There is a need to assess the
effectiveness, cost-effectiveness and ethical impacts of
PPIR through high-quality methodological research
[31–37].
We recently reported a systematic review and meta-
synthesis of factors affecting the recruitment of partici-
pants into depression trials [38] to help us to develop
and evaluate an intervention for recruiting participants
into mental health trials, using the Medical Research
Council (MRC) complex interventions framework [39].
We developed a conceptual framework, which highlighted
that the decision by patients to enrol as subjects in trials
involves a difficult deliberation involving ‘risk’ [38]. This
includes potential risks of stigma, of ‘losing out’ by being
randomised to the ‘wrong’ intervention arm, or of en-
countering adverse effects of trial involvement, against
potential rewards such as a personal need to access treat-
ment and support. Outside of the mental health context,
perceptions of risk have also been shown to impact on pa-
tients’ decision to enrol in trials [40–44]. We have also
undertaken a qualitative study with patients who declined
to participate in a trial, which highlighted the need to re-
search the presentation and provision of accurate and ef-
fective trial information in which patients and the public
play a seminal role [45].
There is some emerging observational evidence that
mental health trials with more PPIR are associated with
an increased likelihood of achieving their recruitment
targets [46], although studies in other clinical settings
have had variable outcomes [47]. PPIR may have a role
in reducing patient perception of risk in trials and, as a
consequence, may increase trial enrolment. Patients may
perceive trials with PPIR to be improved methodologic-
ally or ethically, or to be more relevant and, therefore,
more likely to influence practice in ways that are import-
ant to them and other patients [25, 26, 48]. Additionally,
the concept of ‘social validation’ suggests that people
may be more willing to comply with a request to enrol
in a trial if they believe that others are already engaged
in a trial, as people tend to compare and base their
beliefs, attitudes and actions on similar others [49–51].
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A survey of public attitudes to research suggests that
PPIR may increase confidence and trust in a trial, if po-
tential participants are reassured that other patients have
advised its design [52, 53]. The authors concluded that:
‘if health researchers communicate the fact that patients
and the public have been involved in the design of their
research when approaching potential study participants,
it might help to boost recruitment’ [52, 53]. However, to
achieve these effects, it is necessary that PPIR is commu-
nicated to patients, but this does not always seem to be
the case as researchers tend not to routinely advertise
PPIR [54, 55]. We aimed to test this hypothesis about
the effects of PPIR on recruitment using a rigorous
evaluation. In this paper, we describe the development
and evaluation of an intervention directly advertising
PPIR in a mental health trial to potential participants.
Objectives
Our objectives were to work with PPIR stakeholders to
develop an intervention directly advertising PPIR in the
design and conduct of a host trial, the ‘Enhancing the
Quality of User Involved care Planning in mental health
services’ (‘EQUIP’) trial, which was recruiting people
with a diagnosis of severe mental illness; and to evaluate
its effectiveness on recruitment by undertaking a rando-
mised controlled trial, embedded in the EQUIP host trial.
Methods
We report the development of the intervention in line
with the Criteria for Reporting the Development and
Evaluation of Complex Interventions (CReDECI 2) [56]
and its evaluation in line with the ‘guidelines for reporting
embedded recruitment trials’ [17].
Trial design: the EQUIP host trial
The EQUIP trial aimed to recruit 480 service users with
diagnoses of severe mental illness to evaluate the cost-
effectiveness of a training intervention for mental health
professionals in enhancing user involvement in care
planning. EQUIP had significant high-quality PPIR and
was awarded the 2014 UK Mental Health Research
Network Prize for ‘Outstanding Carer Involvement’ [57].
EQUIP is a multicentre cluster randomised trial, where
36 community mental health teams in the Midlands and
the North of England were randomly allocated to training
or to usual care. In EQUIP mental health team clusters
were ‘paired’ at the recruitment stage (based on size and
geographic location) and randomised using minimisation
in pairs to training or the control arm. Recruitment in the
paired clusters then operated in parallel.
EQUIP used existing registers maintained by commu-
nity mental health teams to recruit service users. Re-
cruitment was undertaken by the UK Clinical Research
Network Mental Health (CRN MH) clinical studies
officers (CSOs) and research nurses, who, in conjunction
with service users’ care coordinators, were responsible
for accessing service user details, determining eligibility
and mailing trial invitations. Invitations were posted to
patients before randomisation of mental health teams
occurred in EQUIP. To be eligible, patients had to be:
aged 18 years or older; under the care of the community
mental health team; have capacity to provide fully in-
formed consent; and judged by their care coordinator to
be well enough to complete study assessments. The re-
search team did not have access to service users’ details
until service users returned the ‘Consent to Contact’
Form. In the majority of mental health teams, potential
participants who did not respond to the initial invitation
letter were telephoned by a CSO or a member of their
mental health team to determine whether they had re-
ceived the trial invitation and whether they were interested
in taking part. Recruitment and baseline assessment of
participants within each cluster occurred within a 6-week
period, before the training was delivered to the mental
health clusters in the intervention arm. The EQUIP team
aimed to recruit a minimum of 10 participants per cluster
(no upper limit was specified). Details of the EQUIP trial
design have been reported elsewhere [58].
Trial design: the embedded recruitment trial
Recruitment into the embedded trial occurred over an
18-month period (June 2014 to December 2015) until
recruitment into the host trial ceased. A patient-level
randomised controlled trial would have been the most
efficient design for the embedded recruitment trial; how-
ever, this was not practical as it was logistically burden-
some for the EQUIP host trial team to administer. We
therefore adopted a cluster randomised design for the
recruitment trial, using the same mental health team
clusters as in the EQUIP host trial. This had two metho-
dological implications. First, due to the relatively small
numbers of clusters (n = 36), there was a possibility of
imbalance between the patients in the two arms of the
embedded trial. Second, there was also a potential risk
to the validity of the host trial: if the PPIR recruitment
intervention were successful there could be differences
between arms in the numbers and types of patients en-
rolled into the host trial.
We therefore adopted a cross-factorial, embedded
randomised controlled trial design with the EQUIP host
trial intervention allocation, using pairwise allocation. In
the embedded trial, the same cluster pairs as in the
EQUIP host trial were presented for randomisation;
however, we randomised both clusters to receive the
PPIR intervention, or both to the control arm (as op-
posed to one cluster being assigned to the intervention
arm, and the other to the control arm). The priority was
to ensure the integrity of the host trial. Pairwise
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allocation guaranteed that we achieved balance of cluster
allocations between intervention and control arms for
both the EQUIP host trial and for the embedded recruit-
ment trial; this allocation method also ensured the vali-
dity of both the host and embedded recruitment trial
interventions.
Clusters were randomly allocated for their patients to
be sent one of two interventions: the standard invitation
(control group); or the PPIR intervention in addition to
the standard invitation (intervention group). The PPIR
intervention was sent in the same envelope as the
EQUIP trial invitation, which also contained a cover let-
ter, a Participant Information Sheet, a ‘Consent to Con-
tact’ Form and stamped addressed envelope. The
embedded recruitment trial thus measured the incre-
mental benefit of being sent the recruitment interven-
tion. Figure 1 outlines the recruitment flowchart for the
embedded recruitment trial.
Eligibility criteria for participants: embedded
recruitment trial
The recruitment trial included all patients identified as
potentially eligible for the EQUIP host trial: there were
no additional inclusion or exclusion criteria.
The recruitment intervention: the PPIR communication
and its development
We developed a recruitment intervention communicat-
ing PPIR guided by the MRC complex interventions
framework [39], informed by Participatory Design ap-
proaches with end users [59, 60]. As described earlier,
the hypothesised mechanism was reducing the percep-
tion of risk in trial enrolment, informed by our prior sys-
tematic review [38] and qualitative study [45],‘social
validation’, emerging from social comparison theory [49,
51] and survey evidence [52, 53]. We searched the latest
Cochrane systematic reviews to determine frequently
used recruitment and retention interventions [11, 61].
We reviewed the EQUIP host trial recruitment strategy
and held discussions with the EQUIP team to determine
a simple, systematic, feasible and acceptable method of
delivering the PPIR intervention. Given that the recruit-
ment occurred through mental health teams and pa-
tients were being approached to enter the host trial by
postal invitations, we selected a leaflet format as the de-
livery mechanism to communicate PPIR. We then orga-
nised an expert workshop involving 27 key stakeholders
including 10 service users with severe mental illness and
two carers of people with severe mental illness, who
were either EQUIP PPIR members or belonged to the
Fig. 1 Flow diagram for the embedded recruitment trial. An overview of the flow of mental health teams and their patients in the embedded
trial, based on the ‘guidelines for reporting embedded recruitment trials’, which adapts Consolidated Standards of Reporting Trials (CONSORT) for
embedded recruitment trials [17]
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EQUIP trial target population. Other stakeholders present
were: five principal investigators/researchers with expertise
in undertaking mental health trials; three patients with
physical health problems; two researchers with expertise in
PPIR; two mental health trial recruiters; two Research
Ethics Board members and a consultant psychiatrist.
During this workshop, stakeholders endorsed the use
of the of the leaflet format for advertising PPIR with the
aim of improving recruitment. Working in small breakout
groups (each group comprised of a mix of researchers and
PPIR members), and then reconvening, stakeholders dis-
cussed and agreed seven ‘core principles’ for the leaflet ad-
vertising PPIR to potential trial participants (see Table 1).
In line with the principles of Participatory Design, par-
ticipants were asked to design their ideal PPIR leaflet ac-
cording to the ‘core principles’ in four breakout groups
using appropriate materials. Each of the four groups pre-
sented their prototype leaflets to the wider group, in-
cluding the key elements of the design. Members then
voted for which of the four leaflets they thought was
best overall for attracting potential participants. The
top-rated leaflet contained similar elements to the other
leaflets, including: making a clear and direct appeal for
potential participants to join the trial; positive photo-
graphs of people with mental health problems which
avoided the typical media image of people holding their
heads in their hands, which members discussed as stig-
matising [62]; highlighting benefits to future patients
and convenience; the option to withdraw from the trial
without giving a reason; and approval by an independent
Research Ethics Committee.
Two of the PPIR members of EQUIP who were
present at the workshop (LC and DM) – one a carer and
the other a service user – volunteered to be photo-
graphed and featured in the EQUIP PPIR leaflet. Both
PPIR members had active and ongoing involvement in
EQUIP, one as a co-applicant and a member of the Trial
Management Team; and both as part of the training
team who delivered the user-involvement training inter-
vention to the host trial intervention clusters. We
worked closely with LC and DM to develop a bespoke
leaflet for the EQUIP host trial, in line with the ‘core
principles’ and taking into account key elements from
the four leaflets created during the workshop. Once the
initial version was developed, we asked for contributions
from the EQUIP host trial researchers (chiefly to check
for accuracy); their input did not change the content or
format of the leaflet. The leaflet was then sent to a pro-
fessional graphic designer in a company with significant
expertise in designing patient communication materials
(www.makingsense.co.uk). The design brief highlighted
the agreed ‘core principles’ (Table 1) and related solely
to the visual presentation of the leaflet and not the con-
tent. Two versions of the leaflet were initially designed
and presented to the EQUIP team and PPIR members,
who voted on their preferred design. Voting gave priority
to PPIR members, who also provided comments in three
rounds of iterations before the final design was agreed.
These comments related to the colours and visual pres-
entation, and the content did not change. Table 2 out-
lines the presentation and content of the final leaflet,
which is also attached as Additional file 1.
Outcome measures
In the EQUIP host trial, CSOs or mental health teams
telephoned patients who did not initially respond to the
postal invitation in poor recruiting clusters. There is evi-
dence that telephone follow-up prompting of patients
who do not respond to invitations to participate in trials
significantly increases recruitment [11]. The host trial
recruiters undertook telephone follow-ups as, and when,
necessary which meant that not all clusters had the tele-
phone follow-ups.
Our pre-planned primary outcome was, therefore,
chosen to assess the effect of the PPIR leaflet, without
potential contamination of the telephone follow-ups.
The primary outcome for our embedded recruitment
trial was the proportion of participants in each group
who were consented and enrolled into the EQUIP host
trial after responding to the postal invitation (i.e. the
proportion of participants who responded and enrolled
without the need for a telephone follow-up reminder).
The secondary outcomes were:
1. The proportion of patients in each group who
positively responded without the need for a
telephone follow-up reminder (note this differs from
the number actually consented and enrolled, due to
for instance, the EQUIP trial exclusion criteria)
2. The total proportions of patients in each group who
were consented and enrolled, including telephone
follow-up of initial nonresponders
Table 1 Core components of the patient and public
involvement in research (PPIR) communication leaflet
intervention
1. The intervention advertising PPIR was in a leaflet format
2. The leaflet was in a booklet style
3. The leaflet was written in plain language, with an informal,
conversational style
4. The leaflet included photographs of the PPIR patients and carers, who
in their own voice describe how they were involved in the trial and
what their impact has been
5. The leaflet included photographs of the research team
6. The leaflet aimed to show that PPIR was taken seriously and was not
tokenistic, and aimed to provide an honest account of PPIR
7. The leaflet aimed to be eye catching: bold, bright print, large font,
colourful
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3. The numbers of clusters in each group needing to
conduct telephone follow-ups due to low postal
response. This outcome takes into account the
potential resource implications of a mental health
clinician or a trial recruiter telephoning patients
who do not respond to the trial invitation
Sample size calculation
The sample size calculations for the EQUIP trial have
been published in the original protocol [58].
As is usual with a trial embedded within a host trial,
we did not undertake a formal power calculation to de-
termine the sample size [15], since the sample size was
constrained by the number of mental health teams and
patients being approached in the EQUIP host trial. Our
sample size was the total number of service users invited
to participate in EQUIP from the 34 available clusters at
the time of implementing the embedded trial, which was
8182 potential participants. We did not undertake a
post-hoc power calculation as this is arguably a futile
exercise, since the power of a trial is expressed in the
confidence interval generated from the outcome analysis
[63] (see ‘Results’ section).
Randomisation
Randomisation was undertaken by the host trial statisti-
cians (NO’L and CR), who were independent from the
delivery of the trial interventions for both the host and
embedded recruitment trials. Randomisation in the
EQUIP host trial was stratified by cluster pairing, the
site/region of each cluster and the caseload size of each
cluster. For the recruitment trial, we used the same clus-
ter pairing as the host trial and allocated each cluster
pair by block-randomisation with permuted block sizes
of 2, 4 and 6, using a computerised randomisation
programme. Service users did not know that they were
part of a trial of a recruitment intervention so were blind
to the study hypothesis. CSOs and research nurses
undertaking trial recruitment and mental health team
clusters were also blind to the group to which clusters
were allocated.
Statistical methods
We obtained baseline data on cluster size (patient list
size), deprivation, care quality rating and patient satis-
faction with clinical care. Deprivation used the Index of
Multiple Deprivation (IMD) rank averaged across
Lower-layer Super Output Areas for each cluster’s
Clinical Commissioning Group [64]. Care quality and
patient satisfaction data were obtained at the cluster
level from the Care Quality Commission which is the
independent regulator of health and social care in
England [65]. Patient satisfaction focussed on the expe-
riences of service users who receive care and treatment
within the mental health teams. Preliminary graphical
and tabular examination of the data explored baseline
comparability of trial arms and representativeness of
the sample in terms of the clusters and the overall
eligible population.
Data analysis used generalised linear mixed models
[66] to estimate the effect of the recruitment interven-
tion. As the unit of randomisation was the cluster pair,
we fitted a three-level, random effects logistic model
which pertained to the individual patient, clustered
within mental health teams, and clustered within paired
mental health teams. We adjusted for mental health
team cluster size, levels of deprivation and care quality
rating (we did not include patient satisfaction with
clinical care in the model due to incomplete data). We
present the marginal mean difference in proportions, as
well as odds ratios (ORs), to assist with interpretation.
Standard errors and confidence intervals for cluster mar-
ginal effects were calculated using the Delta Method.
Given that the EQUIP randomisation occurred after the
embedded trial randomisation, there was no plausible
causal effect of the EQUIP intervention on recruitment
so we did not test for an interaction between the EQUIP
intervention and the recruitment intervention. Fisher’s
exact test was used to test for association between
Table 2 Content and layout of the finalised patient and public involvement in research (PPIR) leaflet
Presentational elements Content
• Four-page booklet format
• Photographs of the EQUIP trial team together with PPIR
members on the front and back pages
• Written in plain language; informal, conversational style
• Contained several photographs of the PPIR members,
including one of them designing the leaflet
• Quotations written by PPIR members
• Use of large font sizes and bright colours
• Front and back pages advertised award of ‘outstanding
carer involvement’ to EQUIP
• Front page stated that ‘real patients and carers’ had informed
in the design of the study, and asked patients to consider taking
part in EQUIP
• Middle pages of the leaflet contained photographs of PPIR members
• Quotations by PPIR members described why they thought the
study was important
• A section highlighting issues felt to be important to patients including:
helping future patients, convenience, confidentiality, approval by a
Research Ethics Committee
• Quotation by EQUIP chief investigator about close working with PPIR
members
• Contained contact details of the study team
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recruitment trial arm and the need for telephone follow-
up. Analyses used the intention-to-treat principle and
were conducted using Stata, version 14 (Stata Corp.,
College Station, TX, USA).
Results
Thirty-eight community mental health team clusters were
recruited and randomised. One cluster pair (two clusters)
could not be included as the EQUIP recruitment started
before the embedded trial could begin. Another cluster
pair withdrew from the EQUIP trial after randomisation,
but prior to the mailing of invitation letters to their pa-
tients, and so are not included in the analysis. Eight
thousand one hundred and eighty-two patients in 34
clusters were sent the standard EQUIP trial invitation
letter or the addition of the PPIR intervention – see
Fig. 1, flow diagram for the embedded recruitment trial.
Table 2 outlines the characteristics of the mental health
clusters and patients. Comparison of cluster baseline
characteristics showed that clusters in the intervention
arm were larger (544 mean patient list size versus 323);
located in more deprived areas (IMD quintile median
1.5 versus 2.5); and had fewer mental health team clus-
ters rated as ‘good’ for care quality (11.1% versus
18.8%). Patients in the intervention and control arms
were broadly similar in age and gender distribution.
Primary outcome
For the primary outcome of the proportions consented
and enrolled into the EQUIP trial, 4% of patients sent
the PPIR communication were enrolled compared with
5.3% of the control group (Table 3). Mixed-effects logis-
tic regression showed that the recruitment intervention
was not effective for improving recruitment rates [OR =
0.75, 95% CI = 0.53 to 1.07, p = 0.113]. The average mar-
ginal effect of the intervention on the probability of en-
rolment was −0.0123 [95% CI = −0.0282 to 0.0036].
Secondary outcomes
1. Responding positively to the invitation, without
telephone follow-up: there was no difference
between the intervention and control groups, with
7.3% of potential participants sent the recruitment
intervention responding positively, compared with
7.9% in the control group: adjusted OR = 0.74, 95%
CI = 0.53 to 1.04, p = 0.082. The average marginal
effect of the intervention on the probability of
positive response was −0.0208 [95% CI = −0.0451
to 0.0035].
2. All positive response (including telephone follow-up):
there was no difference between the intervention and
control groups, with 9.2% of the intervention group
responding positively, compared with 10.0% in the
control group: adjusted OR = 0.74, 95% CI = 0.51 to
1.09, p = 0.125. The average marginal effect of the
intervention on the probability of all positive response
was −0.0343 [95% CI = −0.0795 to 0.0108].
3. Number of clusters requiring telephone follow-up of
nonresponsive patients: this showed that there was
no association between the recruitment trial arm
and the need for a telephone reminder, with 66.7%
in the PPIR group, compared with 75% of control
group: Fisher’s exact test p value = 0.715.
Harms
We tested a two-tailed hypothesis, which accepted that
sending the recruitment intervention to potential partici-
pants could cause benefit or loss to recruitment for the
host trial. Patients not being recruited presents a loss to
the host trial; however, for the patient, not being en-
rolled into the trial may not be harmful and may in fact
be the best thing for them to make an informed decision
that suits them without encountering the potential
inconvenience or negative consequences of trial partici-
pation. The primary and secondary outcomes were de-
signed to demonstrate any potential harms to the
EQUIP host trial in terms of reduced enrolment in the
intervention group. The results demonstrate that the re-
cruitment intervention was ineffective for increasing
Table 3 Baseline information for mental health cluster teams
and patients, by allocation
Mental health team cluster
Baseline factors
PPIR group Control group
List size, mean (SD) 544 (273) 323 (191.6)
IMD quintile, median (range)
[1 =most deprived; 5 = least deprived]
1.5 (1–4) 2.5 (1–5)
Care Quality Commission rating
Good, n (%) 2 (11.1%) 3 (18.8%)
Requires improvement, n (%) 8 (44.4%) 6 (37.5%)
Rating suspended, n (%) 8 (44.4%) 4 (25%)
Not yet inspected, n (%) 0 (0%) 3 (18.8%)
Patient satisfaction with carea, mean (SD)
[10 = highly satisfied]
6.6 (0.3) 6.9 (0.2)
Patients expressing interestb:
Male, n (%) 151 (38.9%) 81 (36.8%)
Female, n (%) 237 (61.1%) 139 (63.2%)
Patients enrolledb:
Male, n (%) 76 (36.2%) 49 (36%)
Female, n (%) 134 (63.8%) 87 (64%)
Mean age, years (SD) 48.5 (12.8) 45.5 (9.3)
IMD Index of Multiple Deprivation, PPIR patient and public involvement in
research, SD standard deviation
aPatient satisfaction survey score data available for 32 clusters
bBaseline information only available for observed sample and not for
entire cluster
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enrolment rates for all outcomes measured. A second
potential harm to the host trial was the potential differ-
ences in the numbers and types of patients enrolled into
the host trial between the intervention and control
groups. We sought to minimise this potential harm by
adopting the cross-factorial design, and making baseline
comparisons between the intervention and control groups.
Baseline comparison of the intervention and control
groups found no differences. We did not measure other
potential harms, such as perceptions of increased pressure
to participate in the intervention group.
Discussion
Summary of main findings
We undertook an embedded trial to evaluate the effective-
ness on recruitment of directly advertising PPIR to poten-
tial trial participants. In this group of patients with severe
mental health problems, the overall rates of response and
participation were low, although this was in line with simi-
lar studies [18]. For our primary outcome, we found that
being sent the intervention was not effective for improving
recruitment rates. Our secondary outcomes found that
directly advertising PPIR did not make a positive dif-
ference to any other outcomes.
Strengths and limitations
To our knowledge, this multicentre trial involving 8182
patients is the largest-ever trial embedded in an ongoing
trial to have been undertaken to evaluate the effective-
ness of an intervention on trial recruitment [11] as well
as the largest to evaluate the impact of patient and pub-
lic involvement [31, 47]. Recruitment trials embedded
within host trials are often plagued by the problem of
small sample sizes as embedded trials are reliant upon
the numbers of patients approached by the host trial.
These numbers are not usually sufficient to show small
but important differences in recruitment [11, 15].
The EQUIP host trial had award-winning high-quality
PPIR. Additionally, the development of the recruitment
intervention and its evaluation involved close collabor-
ation with PPIR members. Both PPIR and recruitment
are considered complex interventions [55, 67]. In our
trial we used the MRC complex interventions framework
to systematically develop a theory-informed recruitment
intervention and evaluate it in a rigorous way, using real
patients being approached to make a real decision about
participation in an ongoing trial. With increasing calls
and now guidance for measuring the impact of PPIR
[68, 69], our work provides randomised evidence in a
field that is very much lacking such evidence.
Cluster randomised designs are often used to evaluate
the effectiveness of recruitment interventions [70–72],
as they are often the most logistically feasible way to de-
liver recruitment interventions embedded in ongoing
host trials. We recognise that cluster randomised trials
can be susceptible to a range of methodological prob-
lems [73, 74]. Due to logistic and operational reasons, it
was not possible to undertake a patient-level randomised
trial, so we adopted a cluster randomised trial design,
which was a design agreeable to the host trial team, and
protected the host trial from potential biases introduced
by the recruitment intervention such as differential re-
cruitment and imbalance in the characteristics of pa-
tients recruited into the host trial as a consequence of
the PPIR intervention. The outcome of the random allo-
cation led to there being more and larger clusters in the
intervention arm of the recruitment trial. However, this
imbalance was a result of the random allocation and oc-
curred by chance. This was a compromise and without
this design we would not have been able to conduct the
embedded recruitment trial, and we later adjusted for
cluster size in the analyses. The randomisation of matched
cluster pairs also has some potential problems, such as
some pairs of clusters being more closely matched than
others, so minimisation in this instance may have been a
better option. However, again it was not feasible to under-
take the minimisation because logistically, the least bur-
densome option for the host trial team was to use the
same cluster pairs that they were using in the host trial.
There is an argument that the impact of involvement
within any particular project is somewhat unpredictable,
and that there is a need to provide details of context in
accounts of PPIR [75]. Furthermore, there is also a need
to understand how context and mechanism influence
the impact of PPIR [75]. We did not have sufficient re-
sources to undertake formal qualitative interviews to
understand the mechanism of impact. However, we are
currently undertaking two other embedded trials of this
intervention directly advertising PPIR to potential trial
participants to better understand the context and mech-
anism of impact. In one of these linked trials, we are
undertaking user-testing of the PPIR recruitment inter-
vention with patients and families to enable the revision
and refining of the intervention to make it more appro-
priate to their context. We are also undertaking qualita-
tive interviews with people who enter the host trial to
explore their views of the PPIR intervention and deter-
mine its impact on their decision-making.
Comparison with existing trial literature
Our findings contrast with a survey where 44% members
of the British public responding to a hypothetical ques-
tion indicated that they would be more likely to enrol in
a trial if they found that patients had advised in its de-
sign [53]. The authors of this survey reported that very
few people thought that PPIR would reduce their confi-
dence in a trial. We found that patients actually invited
to enter a real trial were no more likely to enrol when
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they were sent a leaflet about PPIR. Research investigat-
ing hypothetical and actual willingness to enrol in a trial
found that only 20% of participants stating hypothetical
willingness to enter a trial actually enrolled and that
statements of hypothetical willingness to participate in
future trials may overestimate true enrolment [76].
A systematic review to assesses the impact of PPIR on
recruitment and retention in trials has found that while
PPIR is consistently associated with improved retention,
the evidence for impact on enrolment is variable and in-
consistent [47]. A number of studies identified by this
review found either no significant positive effect of PPIR
on trial recruitment, or in one case involving the recruit-
ment of African-Americans being recruited through
three different sources, that the non-PPIR arm was more
effective at improving recruitment [77]. Our present
findings are, therefore, in line with the trial literature
evaluating the impact of PPIR on recruitment.
Explaining our findings and potential mechanisms of action
Beyond advertising PPIR intervention simply being inef-
fective for improving trial recruitment and response
rates, there are a range of other possible reasons for our
present findings. First, it is possible that people in the
PPIR arm did not read the leaflet. The leaflet was sent
by post in a large recruitment pack with several other
documents. Those sent the recruitment pack may not
have opened it, and those who did may not have read
the PPIR recruitment leaflet. We were not able to deter-
mine how many people read the recruitment leaflet and
our intention-to-treat analysis may have underestimated
the effects of the active intervention components.
Second, it is also not clear whether those sent the leaflet,
and who read it, understood the message in the leaflet and
what PPIR meant for the trial that they were being asked
to enrol into. Conversely, there is some research evidence
indicating that patients receiving supplementary written
information about a trial in the form of a booklet or leaflet
have improved knowledge about the trial [78, 79]. It is
possible that those who read the leaflet were more likely
to make a more informed decision about not enrolling in
the trial, which would have been a good decision for the
patient, but a bad outcome for the trial. Unfortunately, in
this population it was not possible to obtain estimates of
the effect of the recruitment intervention for those who
were randomised to receive the leaflet, who also actually
read it, and how they interpreted the message.
Third, there are a range of mechanisms by which PPIR
might influence recruitment, including on the trial de-
sign and trial conduct. Thus, the role of PPIR might lead
to sensitive issues being handled better [80] or enhance
trial quality and appropriateness, making them more ef-
fective [25, 35]. These mechanisms call into question the
mechanism used in our trial, which is that advertising
PPIR might improve recruitment. Additionally, the high-
quality PPIR in EQUIP may have meant that the PPIR
benefits may have been already optimised in EQUIP.
The addition of the PPIR recruitment intervention may,
therefore, have been irrelevant since the PPIR under-
taken in EQUIP may have been sufficient to promote
participant recruitment. However, the overall enrolment
rates in EQUIP were low, with rates similar to other tri-
als recruiting from similar populations [18, 81], so this
does not suggest that the significant PPIR in EQUIP im-
proved recruitment when compared with other trials.
This contrasts with an observational study which found
that studies that involved patients to a greater extent were
more likely to have achieved recruitment targets [46].
Fourth, we developed our conceptual framework
around the decision to enter trials using depression as
the case exemplar, yet our recruitment intervention, in-
formed by the conceptual framework, was evaluated in a
population of patients with severe mental illness (who
may or may not have had depression). Depression is the
leading cause of disease burden worldwide [82, 83], and
when we initiated our programme of work we antici-
pated that we would develop and then test the recruit-
ment intervention using a depression trial. However, we
found it impossible to recruit a host depression trial in
order to evaluate the recruitment intervention, despite
directly contacting 14 potential host trials registered on
the National Institute for Health Research (NIHR) trials
portfolio, seeking support from the Clinical Research
Network Mental Health, which contacted trials on our
behalf, and advertising for host trials via the UK Trial
Managers’ Network. The main reason why a depression
host trial was not forthcoming was due to a mismatch
between the recruitment timelines of potential host trials
and that of the embedded recruitment trial: the majority
of host trials approached were either close to finishing
participant recruitment, or were in the early phase of
set-up, meaning that it was not possible to align host
trial participant recruitment with the embedded recruit-
ment trial. Two other depression trials reported that
they already intended to advertise their PPIR activities to
potential participants. This failure to recruit a depression
trial may have impacted on the embedded trial outcomes
as the intervention may not have been as relevant for
the population in the EQUIP trial of people with severe
mental illness. However, approximately 47% of the
EQUIP population had comorbid depression. Addition-
ally, mental health disorders in general have the stron-
gest established history of PPIR in the UK [84–86], and
there is some evidence that the use of PPIR is signifi-
cantly associated with successful recruitment across a
range of mental health trials, including severe mental ill-
ness, psychoses and depression [87, 88]. Furthermore,
the Health Research Authority survey suggesting direct
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communication of PPIR to potential participants indi-
cated that this approach could be used in all disease
areas [52, 53]. We developed the PPIR intervention
closely with the EQUIP trial and the use of the interven-
tion was strongly endorsed by stakeholders.
Fifth, we used the concept of social validation to in-
form our recruitment intervention. The concepts of risk
and social validation exist across all disease areas, how-
ever, not just depression. Social validation has also been
used successfully as a trial recruitment intervention, with
an embedded recruitment trial of text messages containing
quotes from existing participants significantly increasing
randomisations [89]. However, in our trial, social valid-
ation came from patients as research partners, rather than
from patients as trial participants. This may have had an
influence on our findings.
Finally, informal discussions of our findings with
stakeholders suggested that the stigma associated with
mental illness may have led to a negative impact of the
PPIR intervention. Stigma, both towards others with
mental health problems, as well as mental health stigma
‘internalised’ towards the person’s own self are well-
documented and can deter people with mental health
problems from seeking health care [90–92]. In our re-
cruitment trial, stigma may have meant that awareness
that EQUIP had significant PPIR from individuals with
mental health problems may have made some people re-
luctant to enrol. Additionally, there may have been a
perception of a lack of ‘professionalism’ in trial design
and conduct, suggested by the significant involvement of
patients and carers, as opposed to the trial being wholly
conducted by ‘trained professional researchers’. Stigma
and a perceived lack of professionalism may have com-
bined to make some people disinclined to enrol in the
trial. Other PPIR members and stakeholders involved in
other trials suggested that the leaflet lacked representa-
tiveness and commented that the images of people in
the leaflet were not representative of them, that: ‘the
people in this leaflet do not look like me’. Diversity in
representativeness of PPIR members has been discussed
in the trial literature, and arguments have been made for
the need to engage with PPIR representatives who reflect
the diversity of the study population [93]. Due to resource
constraints, we were unable to undertake qualitative inter-
views with the people sent the PPIR communication in
order to explore and understand patient views of the
intervention.
Implications for recruitment practice, public policy and
research
It is important to highlight here that while we found that
directly communicating PPIR using a leaflet to potential
trial participants was not effective for improving trial re-
cruitment, this is not the same as PPIR being ineffective
or harmful to trials in general. Our experience in under-
taking this trial, and that of the EQUIP host trial, is that
PPIR is very effective for developing interventions that
can be delivered and evaluated in trials. However, we did
not actually evaluate this, as the recruitment interven-
tion was about direct communication of PPIR to poten-
tial participants. It is quite possible that rather than
directly communicating PPIR to potential participants,
what PPIR achieves in terms of making a trial and its in-
terventions more attractive, acceptable and patient-
centred is what is important in terms of its impact. More
rigorous trials are needed to evaluate the impact of
PPIR. Here, our findings point to a direction of focus for
evaluating the impact of PPIR in trials, in informing the
design and conduct of trials, but not as a means for dir-
ect recruitment. Policy-makers should be aware that
PPIR is not a panacea and should fund more systematic
evaluations of the impact of PPIR. Findings from this re-
search will be sent to the authors of the Cochrane sys-
tematic review of interventions to improve recruitment
to trials, for inclusion in future systematic reviews [11].
There is some evidence to suggest that PPIR may be
effective for improving retention in trials [47]. Partici-
pants in EQUIP are currently in the follow-up phase.
We aim to determine whether direct communication of
PPIR improves retention in EQUIP. It is unclear to what
extent different versions of this intervention might have
had different impacts in different trial contexts and
patient populations. For example, while the PPIR inter-
vention was developed with PPIR partners, it was not
user-tested with potential trial participants. There is
some evidence that performance-based user-testing of
trial information can identify strengths and weaknesses
in trial information materials and make them fit for pur-
pose [94, 95]. Here, the usability, acceptability and acces-
sibility can be improved using semistructured interviews
and iterative testing cycles [96]. A user-tested version of
the intervention may have impacted on how potential
participants responded. A user-tested version of the PPIR
intervention is currently being evaluated in the Culturally-
adapted Family Intervention (CaFI) study recruiting
African-Caribbean people diagnosed with schizophrenia
[97]; another version of the intervention is currently being
evaluated in a study investigating early signs of dementia.
Our broad aim is to aggregate the results across the dif-
ferent trials to obtain a more precise estimate of effect,
as well as to explore the effectiveness of the intervention
across different research contexts and patient populations.
Our trial highlights the potential benefits of process
evaluation in embedded recruitment trials by adopting
qualitative methods to explore patients’ use and views of
recruitment interventions. This would make it necessary
for trialists to obtain the necessary ethical permissions
to approach people sent such recruitment materials to
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gain insights into the mechanisms and contexts of these
interventions [98]. There are potential problems, as
process evaluation would add significant costs to embed-
ded trials and may add significant complexity to the
process of embedding a trial, which might act as a bar-
rier to adoption. In addition, however, our prior work
with people who declined to enter a trial highlights that
even those who declined to enter a trial reported that
they do not mind being approached and, in addition,
were happy to explore their trial participation decisions
[45]. We are currently undertaking an additional qualita-
tive study to explore the views of people who are sent a
similar PPIR recruitment intervention as part of the trial
embedded in the CaFI study [97].
Conclusions
This embedded recruitment trial found no benefits of
directly communicating PPIR on response, consent
or enrolment rates. Further embedded trials of these ma-
terials are being conducted to explore how the impact of
the intervention may vary by intervention type, trial con-
text and patient population. A more comprehensive co-
hort of embedded trials of recruitment interventions
across the trials portfolio could lead to a rapid develop-
ment of the evidence base around recruitment to make
trials more acceptable and accessible to patients.
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